PIPELINE OVERVIEW

pipeline-sep-2018-002

The company’s leading program is a differentiated PPAR gamma agonist (MIN-102) being developed for X-linked Adrenoleukodystrophy (X-ALD) that has the potential to treat both cerebral ALD (cALD) and adrenomyeloneuropathy (AMN), the two main forms of X-ALD.

MIN-102 has initiated a phase 2/3 clinical trial in adult AMN patients.